scholarly journals Renin–angiotensin–aldosterone system gene polymorphisms in gestational hypertension and preeclampsia: A case–control gene-association study

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Xun Li ◽  
Hongzhuan Tan ◽  
Shujin Zhou ◽  
Shimin Hu ◽  
Tianyi Zhang ◽  
...  
2012 ◽  
Vol 132 (10) ◽  
pp. 2464-2468 ◽  
Author(s):  
Beatrice Melin ◽  
Anna M. Dahlin ◽  
Ulrika Andersson ◽  
Zhaoming Wang ◽  
Roger Henriksson ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. e026777 ◽  
Author(s):  
Laura Jane Smyth ◽  
Marisa Cañadas-Garre ◽  
Ruaidhri C Cappa ◽  
Alexander P Maxwell ◽  
Amy Jayne McKnight

BackgroundChronic kidney disease (CKD) is defined by abnormalities in kidney structure and/or function present for more than 3 months. Worldwide, both the incidence and prevalence rates of CKD are increasing. The renin-angiotensin-aldosterone system (RAAS) regulates fluid and electrolyte balance through the kidney. RAAS activation is associated with hypertension, which is directly implicated in causation and progression of CKD. RAAS blockade, using drugs targeting individual RAAS mediators and receptors, has proven to be renoprotective.ObjectivesTo assess genomic variants present within RAAS genes, ACE, ACE2, AGT, AGTR1, AGTR2 and REN, for association with CKD.Design and data sourcesA systematic review and meta-analysis of observational research was performed to evaluate the RAAS gene polymorphisms in CKD using both PubMed and Web of Science databases with publication date between the inception of each database and 31 December 2018. Eligible articles included case–control studies of a defined kidney disease and included genotype counts.Eligibility criteriaAny paper was removed from the analysis if it was not written in English or Spanish, was a non-human study, was a paediatric study, was not a case–control study, did not have a renal disease phenotype, did not include data for the genes, was a gene expression-based study or had a pharmaceutical drug focus.ResultsA total of 3531 studies were identified, 114 of which met the inclusion criteria. Genetic variants reported in at least three independent publications for populations with the same ethnicity were determined and quantitative analyses performed. Three variants returned significant results in populations with different ethnicities at p<0.05: ACE insertion, AGT rs699-T allele and AGTR1 rs5186-A allele; each variant was associated with a reduced risk of CKD development.ConclusionsFurther biological pathway and functional analyses of the RAAS gene polymorphisms will help define how variation in components of the RAAS pathway contributes to CKD.


Aging ◽  
2016 ◽  
Vol 8 (7) ◽  
pp. 1364-1383 ◽  
Author(s):  
Jacob J.E. Koopman ◽  
Jeroen Pijpe ◽  
Stefan Böhringer ◽  
David van Bodegom ◽  
Ulrika K. Eriksson ◽  
...  

2013 ◽  
Vol 28 (4) ◽  
pp. 336-347 ◽  
Author(s):  
Daniela Vivenza ◽  
Mauro Feola ◽  
Ornella Garrone ◽  
Martino Monteverde ◽  
Marco Merlano ◽  
...  

Background Anthracyclines are among the most active drugs against breast cancer, but can exert cardiotoxic effects eventually resulting in congestive heart failure (CHF). Identifying breast cancer patients at high risk of developing cardiotoxicity after anthracycline therapy would be of value in guiding the use of these agents. Aims We determined whether polymorphisms in the renin-angiotensin-aldosterone system (RAAS) and in the glutathione S-transferase (GST) family of phase II detoxification enzymes might be useful predictors of left ventricular ejection fraction (LVEF) kinetics and risk of developing CHF. We sought correlations between the development of cardiotoxicity and gene polymorphisms in 48 patients with early breast cancer treated with adjuvant anthracycline chemotherapy. Methods We analyzed the following polymorphisms: p.Met235Thr and p.Thr174Met in angiotensinogen ( AGT), Ins/Del in angiotensin-converting enzyme ( ACE), A1166C in angiotensin II type-1 receptor ( AGTR1A), c.-344T>C in aldosterone synthase ( CYP11B2), p.Ile105Val in GSTP1. Additionally, we analyzed the presence or absence of the GSTT1 and GSTP1 genes. A LVEF <50% was detected at least once during the 3 years of follow-up period in 13 out of 48 patients (27.1%). Conclusion RAAS gene polymorphisms were not significantly associated with the development of cardiotoxicity. GSTM1 may be useful as a biomarker of higher risk of cardiotoxicity, as demonstrated in our cohort of patients (p=0.147).


2000 ◽  
Vol 3 (4) ◽  
pp. 321-325 ◽  
Author(s):  
Jürgen Deckert ◽  
Jobst Meyer ◽  
Marco Catalano ◽  
Monica Bosi ◽  
Philipp Sand ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document